Literature DB >> 11231712

Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia.

A Klepfish, A Berrebi, A Schattner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11231712     DOI： 10.1001/archinte.161.5.767

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  4 in total

1.  [Local use of tranexamic acid in ENT surgery].

Authors:  J Abrams
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

2.  Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.

Authors:  Joan D Beckman; Quefeng Li; Samuel T Hester; Ofri Leitner; Karen L Smith; Raj S Kasthuri
Journal:  Orphanet J Rare Dis       Date:  2020-07-13       Impact factor: 4.123

3.  Effects of tranexamic acid on human nasal ciliary beat frequency.

Authors:  W Behr; F Horschke; A Nastev; C E Mueller; J U Sommer; B Folz; H Li; U W Geisthoff; B A Stuck; R Birk
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-04       Impact factor: 2.503

4.  Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.

Authors:  Fabio E Ospina; Alex Echeverri; Iván Posso-Osorio; Lina Jaimes; Jaiber Gutierrez; Gabriel J Tobón
Journal:  Colomb Med (Cali)       Date:  2017-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.